Moreover, in many disease states beyond cancers, PARP inhibitors have been explored as potential therapeutics to prevent cell death, tissue damage, and dysfunction-associated pathologies (e.g., cardiovascular diseases, autoimmune and inflammatory diseases, neurodegenerative diseases, stroke, and diabetes) and any associated complications [29,164,165,166,167,168,169,170]. Here, PARP1 is linked to cancer.